Skip to main content
Clinical Trials/NCT02971826
NCT02971826
Completed
Not Applicable

Use of the Thrombectomy Device ReVive™ SE in the Acute Treatment of Stroke

Hospices Civils de Lyon1 site in 1 country1 target enrollmentNovember 30, 2018
ConditionsStroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Hospices Civils de Lyon
Enrollment
1
Locations
1
Primary Endpoint
number of patients with a TICI score of 2b or 3 just after the thrombectomy
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The last marketed thrombectomy devices, named stentretriever, permit a better and faster recanalization in patient with a stroke. The REVIVETM SE is a device designed to restore the brain perfusion in patient with an intracranial artery occlusion. The REVIVETM Se device is not widely use in Europe and in France. The objective of this study is to assess the interest of using this device in the standard care of ischemic stroke in the radiology unit of the hospital Pierre Wertheimer, Lyon. The medical care will not be modified but data will be collected in order to determine whether or not this device is useful for the practice of the radiology unit.

Registry
clinicaltrials.gov
Start Date
November 30, 2018
End Date
June 1, 2019
Last Updated
4 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient with an ischemic stroke detected by Computed Tomography (CT) or Magnetic Resonance Image (MRI)
  • Large proximal arterial occlusion : M1 segment of the Middle cerebral artery (MCA), Internal Carotid Artery (ICA) or Basilar Artery (BA)
  • Last known well (without neurological symptoms) ≤ 8 hours of treatment initiation
  • Score NIHSS ≥4
  • Eligibility on an endovascular procedure using REVIVETM SE device
  • No opposition of the patient to participate at the study

Exclusion Criteria

  • Diagnostic cerebral imaging impossible
  • Distal occlusion
  • Tortuous vessel or other specificity preventing the access of device
  • Vessel diameter \< 1.5 mm
  • Known hypersensibility or allergy to nitinol
  • Subjects not covered by or having the right to social security
  • Deprivation of civil rights (guardianship, safeguard justice)

Outcomes

Primary Outcomes

number of patients with a TICI score of 2b or 3 just after the thrombectomy

Time Frame: up to 2 days

The TICI score is a grading system which evaluate the degree of reperfusion as seen on arteriography

Secondary Outcomes

  • Number of other procedures to treat the patient (thrombolysis, thromboaspiration, etc)(Day 0)
  • Time to obtain the appropriate recanalization (TICI 2b or 3)(At the end of the procedure - Day 0)
  • Number of the other devices use during the thrombectomy (Gidewire, catheter, etc.)(up to 2 days)

Study Sites (1)

Loading locations...

Similar Trials